

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



華潤醫藥集團有限公司

China Resources Pharmaceutical Group Limited

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3320)

GRANT OF WAIVER FROM STRICT COMPLIANCE WITH RULE 14.41(A) OF THE LISTING RULES

Reference is made to the announcement of the Company dated 30 September 2020 in relation to the Company's proposed acquisition of a controlling stake in Boya Bio-pharmaceutical Group Co., Ltd, the announcement dated 23 October 2020 in relation to delay in despatch of the Circular and the announcement dated 14 December 2020 in relation to further delay in despatch of the Circular (the "**Further Delay Announcement**") (collectively, the "**Announcements**"). Unless otherwise defined herein or the context requires, capitalised terms used in this announcement shall have the same meanings as those defined in the Announcements.

As disclosed in the Further Delay Announcement, additional time is required to prepare and finalise, among other things, the financial information to be included in the Circular, and the Company has applied to the Stock Exchange for the Waiver from strict compliance with Rule 14.41(a) of the Listing Rules.

On 14 December 2020, the Stock Exchange granted the Waiver to the Company on the basis that the Company will despatch the Circular on or before 24 December 2020 and disclose details and reasons of the Waiver by way of an announcement. The Waiver applies to this case only and the Stock Exchange may withdraw or change the Waiver if the Company's situation changes.

Shareholders and potential investors should note that the transactions contemplated under the Transaction Documents are subject to the fulfilment of the conditions precedent stated in the Transaction Documents and may or may not proceed. Accordingly, Shareholders of the Company and potential investors are advised to exercise caution when dealing in the securities of the Company.

By Order of the Board
China Resources Pharmaceutical Group Limited
WANG Chuncheng
Chairman

Hong Kong, 15 December 2020

As at the date of this announcement, the Board comprises Mr. WANG Chuncheng as chairman and non-executive Director, Mr. HAN Yuewei, Mr. LI Xiangming and Mdm. WENG Jingwen as executive Directors, Mr. YU Zhongliang, Mdm. GUO Wei, Mr. WANG Shouye and Mr. LYU Ruizhi as non-executive Directors and Mdm. SHING Mo Han Yvonne, Mr. KWOK Kin Fun, Mr. FU Tingmei and Mr. ZHANG Kejian as independent non-executive Directors.